Medical devices, healthcare technology and the business of care
COMPANY INTELLIGENCE

Hepquant, LLC

Explore this company’s associated devices, FDA decisions and regulatory history.

Clinical monitoring equipment, editorial photography

Hepquant, LLC

Regulatory records
1
Linked recall entries
0
Headquarters
Not reported
Brand website
Not reported
COMPANY INTELLIGENCE

What the linked records show

MedtechLedger currently links 1 FDA record to the applicant name Hepquant, LLC. It includes 1 original PMA approval. These are records held by this publication, rather than a count of the company’s entire portfolio.

The dated entries run from Jun 18, 2026 to Jun 18, 2026. Individual filings may concern different products or changes to an existing application; review the identifier and decision scope on each record.

Product code SIO appears in 1 of the 1 linked filings. The collection spans 1 FDA product code and 1 original PMA application family. These figures describe the filings available here; they do not establish the company’s total device sales or market share.

The largest PMA family in this collection is P220016, with 1 linked entry. Follow the parent application and its dated supplements to distinguish the original device scope from later changes.

Applicant mailing address recorded by FDA: 12635 E. Montview Blvd., Suite 175l1, Aurora, CO, 80045. Recorded on P220016, decision dated Jun 18, 2026.

Changes described in PMA records

P220016: HepQuant SHUNT Liver Diagnostic Test

FDA’s recorded scope: Approval for HepQuant SHUNT Liver Diagnostic TestThe HepQuant SHUNT Liver Diagnostic Test is designed for the quantitative detection of 13C-cholate and d4-cholate in human serum from blood samples collected after the intravenous administration of 13C-cholate and the oral ingestion of d4-cholate. The assay generates a Disease Severity Index (DSI) score from the clearance of 13C-cholate and d4-cholate. Sample analysis is conducted by the HepQuant Analytical Test Laboratory.A DSI score below the validated threshold can be used in patients with compensated cirrhosis (Child Pugh Class A), age 22 years or older, undergoing screening or surveillance for esophageal varices to identify those patients unlikely to have large esophageal varices. The DSI score aids in identifying patients unlikely to require esophagogastroduodenoscopy (EGD) at the time of testing.The HepQuant SHUNT Liver Diagnostic Test is not a stand-alone test and should be used in conjunction with other clinical and laboratory findings.

Jun 18, 2026

Subsidiaries and similarly named applicants can have separate records. The links below preserve the applicant and submission identifiers. Source records are linked on each filing.

Regulatory record history

  1. HepQuant SHUNT Liver Diagnostic Test

    P220016 · PMA decision
Source information

Source updated Nov 9, 2026. Retrieved Nov 21, 2026.